SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Clinical Trials
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Teerenstra, S.
Right arrow Articles by Borm, G. F
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Teerenstra, S.
Right arrow Articles by Borm, G. F
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Sample size calculations for 3-level cluster randomized trials

Steven Teerenstra

Department of Epidemiology, Biostatistics and Health Technology Assessment, Radboud University Nijmegen Medical Centre, Nigmegen, The Netherlands, s.teerenstra{at}ebh.umcn.nl

Mirjam Moerbeek

Department of Methodology and Statistics, Utrecht University, Utrecht, The Netherlands

Theo van Achterberg

Centre for Quality of Care Research, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

Ben J Pelzer

Department of Social Science Research Methods, Radboud University Nijmegen, Nijmegen, The Netherlands

George F Borm

Department of Epidemiology, Biostatistics and Health Technology Assessment, Radboud University Nijmegen Medical Centre, Nigmegen, The Netherlands

Background The first applications of cluster randomized trials with three instead of two levels are beginning to appear in health research, for instance, in trials where different strategies to implement best-practice guidelines are compared. In such trials, the strategy is implemented in health care units (`clusters') and aims at changing the behavior of health care professionals working in this unit (`subjects'), while the effects are measured at patient level (`evaluations').

Purpose To guide the choice of number of clusters, number of subjects per cluster, and number of evaluations per subject.

Methods We derive a sample size formula and investigate the influence of sample allocation on power or number of clusters required.

Results The required sample size is the product of the sample size in absence of correlation and two variance inflation factors (VIFs) that describe the clustering of evaluations within subjects and of subjects within cluster, respectively. Because each VIF is expressed in terms of an interpretable Pearson correlation, subject matter knowledge can be incorporated. Moreover, these Pearson's correlations are related to intracluster correlations (ICCs) from comparable, but 2-level cluster randomized trials. Formulas are obtained to guide the sample allocation (number of clusters, subjects, and evaluations) for minimizing total sample size, minimizing the number of clusters, or maximizing power given a budget constraint.

Limitations Empirical estimates of variance components or ICCs from 3-level cluster trials are scarce which limits reliably powering.

Conclusions When parameterized in terms of Pearson correlations, the two variance inflation factors give quantitative insight into the impact of the number of clusters, subjects and evaluations on power. Moreover, subject matter knowledge as well as ICCs from 2-level cluster randomized trials can be incorporated in the sample size calculation, when empirical estimates of variance components or ICCs from a pilot or comparable 3-level study are lacking. Clinical Trials 2008; 5: 486—495. http://ctj.sagepub.com

Clinical Trials, Vol. 5, No. 5, 486-495 (2008)
DOI: 10.1177/1740774508096476


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement